Heart failure (HF) represents a major issue in patients with hypertrophic cardiomyopathy (HCM) as it is one of the leading causes of mortality in these patients. In this educational program, 3 experts discuss how to recognize and diagnose HF in patients with HCM and explore which therapeutic options are currently available for these patients.
This course consists of 3 episodes. Watch all episodes, answer pre- and post-test questions, and start earning CME credits.
This educational program consists of 3 presentations on HF and HCM.
Recognizing and diagnosing heart failure in patients with HCM - Aleš Linhart, MD, PhD - Prague, Czech Republic
Optimal pharmacological management of HCM by clinical manifestations - Pablo García-Pavía, MD, PhD - Madrid, Spain
Evidence-based novel therapies in HCM - Michelle Michels, MD, PhD - Rotterdam, The Netherlands
For questions regarding this activity, please contact us at info@pace-cme.org.
For questions regarding this activity, please contact us at info@pace-cme.org.
This activity has been designed to meet the educational needs of cardiologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with hypertrophic cardiomyopathy.
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and MEDCON International. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for .75 number of credits. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until May 11, 2026. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for .75 contact hour/0.075 CEUs of pharmacy contact hours. The Universal Activity Number for this program is JA0006235-0000-24-082-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
This enduring activity is accredited by the European Board for Accreditation of Continuing Education for Health Professional (EBAC) for 40 minutes of effective education time.
Funding for this educational program was provided by an unrestricted educational grant from Bristol Myers Squibb.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of PACE-CME.
Release Date:
Expiration Date:
